ALCL     RESEARCH GROUPSFEATURED PUBLICATIONSTOOLS  
ERIA

European Research
Initiative of ALK-related
malignancies

RNA biology in hematological cancers

Group Leader:
Brousset Pierre

Contact:
Cancer Research Center of Toulouse (CRCT)
UMR1037 INSERM-UPS-ERL5294 CNRS
Team 7: RNA biology in hematological cancers
Oncopole de Toulouse, Entrée C,
2 avenue Hubert Curien
CS53717
31037 TOULOUSE Cedex 1 - FRANCE
phone: 33-5-82-74-15-75
fax: 33-5-82-74-16-85

Afiliation:
1- Inserm, UMR1037 CRCT, F-31000 Toulouse, France
2- Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
3- CNRS, ERL5294 CRCT, F-31000 Toulouse, France
4- Department of Pathology, Purpan Hospital, Toulouse, France

Funding:
Association pour la recherche contre le Cancer (ARC)
Ligue Nationale / Régionale contre le Cancer
Institut National du Cancer (InCA)
Fondation de France (FdF)
Fondation pour la Recherche Médicale (FRM)
Agence Nationale pour la Recherche (ANR)
Labex TOUCAN

Description:
1- Mechanisms of ALK lymphoma development, regression, relapse and resistance.
2- Expression and role of non-coding RNAs (miRNAs, snoRNAs and lncRNAs) and identification of their downstream target genes involved in classical (proliferation, survival, migration) and new (autophagy, ER Stress) cancer pathways.
3- Mechanisms of ncRNAs regulation (epigenetic control, control of their stability by RNA-BPs or specific endoribonucleases)

Collaborators:
Pr Laurence Brugières’s group
Pr Carlo Gambacorti-Passerini’s group

Publications:
1- Dejean E, Foisseau M, Lagarrigue F et al. ALK+ALCL induce cutaneous HMGB-1-dependent interleukin-8/CXCL8 production by keratinocytes through NF-kappaB activation.
Blood. 2012 May 17;119(20):4698-707.
2- Bergalet J, Fawal M, Lopez C, Desjobert C, Lamant L, Delsol G, Morello D, Espinos E. HuR-mediated control of CEBPbeta mRNA stability and translation http://www.crct-inserm.fr/news-50.htmlin ALK-positive Anaplastic Large Cell Lymphoma.
Mol Cancer Res 2011;9: 485-96.
3- Dejean E, Renalier MH, Foisseau M, Agirre X, Joseph N, de Paiva GR, Al Saati T, Soulier J, Desjobert C, Lamant L, Prósper F, Felsher DW, Cavaillé J, Prats H, Delsol G, Giuriato S, Meggetto F. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
Leukemia. 2011;25:1882-90.
4- Lamant L, McCarthy K, d'Amore E, Klapper W, Nakagawa A, Fraga M, Maldyk J, Simonitsch-Klupp I, Oschlies I, Delsol G, Mauguen A, Brugières L, Le Deley MC. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.
J Clin Oncol. 2011;29:4669-76.
5- Desjobert C, Renalier MH, Bergalet J, Dejean E, Joseph N, Kruczynski A, Soulier J, Espinos E, Meggetto F, Cavaillé J, Delsol G, Lamant L. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.
Blood. 2011 Jun 16;117 (24):6627-37.
6- Giuriato, S., Foisseau, M., Dejean, E., Felsher, D.W., Al Saati, T., Demur, C., Ragab, A., Kruczynski, A., Schiff, C., Delsol, G. and Meggetto, F. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
Blood, 2010, 115(20): p. 4061-70.

Weblinks:


Tools:
Monoclonal antibodies to ALK and other lymphoma-associated antigens.
Conditional cell lines (MEF) and mouse models for NPM-ALK and TPM3-ALK expression

Techniques:
Immunoprecipitation of ribonucleoproteic complexes
Cell fractionation
Biotin pulldown assays
q-RT PCR for miRNAs
Immunohistochemistry
Conditional expression of gene, in vitro, in vivo
Mouse full autopsy, tissue optimal saving, database building